Deslotine

Indonesia • Dexa Medica

Indication

Allergic rhinitis
Desloratadine 5 mg tablet is indicated for the relief of nasal and non-nasal symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) in patients 12 years of age and older.

Urticaria
Desloratadine 5 mg tablet is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with urticaria 12 years of age and older.

Composition

Desloratadine 5 mg

Package

3 strips of 10 tablets

Dosage Forms

Tablet

ATC Classification

R06A

Warning

Alcohol
Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
Caution
This item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.
Pregnancy
Consult Your Doctor
Safety of this item for use during pregnancy has not been established. Please consult your doctor.
Lactation
Not Recommended
This item is not safe for use during lactation.

Dosage

Up to 12 Years

The safety and effectiveness of desloratadine tablets in pediatric patients under 12 years of age have not been established.

12 to 65 Years Old

The recommended dose is 5 mg (one tablet) once daily.

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks):
Should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.

Persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks):
Continued treatment may be proposed to the patients during the allergen exposure periods.

65 Years Old and Above

In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks):
Should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.

Persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks):
Continued treatment may be proposed to the patients during the allergen exposure periods.

Patients with Impaired Hepatic Function

A starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.

Patients with Impaired Renal Function

A starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.